Biogen Stock News

Shares of Biogen Inc fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild cognitive impairment due to Alzheimer'

Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer's drug whose benefits have been widely questioned, a major development in the nation's tug-of-war over the fair value of new

Medicare officials proposed coverage of Aduhelm only for recipients who are enrolled in qualifying clinical trials, potentially limiting sales.

Biogen stock tumbled late Tuesday after U.S. regulators limited which patients can access the controversial Alzheimer''s treatment, Aduhelm.

Gainers: Bed Bath & Beyond BBBY +6%, Orphazyme (ORPH) +4%, Esperion Therapeutics ESPR +4%, Aurora Innovation (AUROW) +4%, Canadian Solar (CSIQ) +3%. Losers: Gogo

CMS has proposed to severely limit coverage of Biogen''s Alzheimer''s therapy Aduhelm by only covering the monoclonal antibody for those currently in clinical trials.

Biogen Inc. shares fell more than 6% in the extended session Tuesday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said it plans to cover the biotech''s controversial Alzheimer''s drug Aduhelm and future others like it only in certain instances. CMS''s proposal is that Food and Drug Administration-approved monoclonal antibodies such as Aduhelm and others in its class would be covered for people with Medicare only if they are enrolled in "qualifying clinical trials," the agency said. The proposed determination is open to public comment for 30 days. If the proposal is finalized, CMS will review each clinical trial submitted to decide whether it meets its criteria. Medicare patients participating in these trials would be eligible to receive coverage of the drug, related services, and other routine costs, CMS said. Aduhelm, the first new treatment for Alzheimer''s in 20 years, was approved by the FDA for the treatment of the neurodegenerative disease in June but its sales have disappointed investors and have been a small portion of what Biogen expected.

CMS has proposed to severely limit coverage of Biogen''s Alzheimer''s therapy Aduhelm by only covering the monoclonal antibody for those currently in clinical trials.

Doctors demanded the FDA revoke its approval for the Alzheimer's drug Aduhelm, which can cause side effects like brain bleeding.

Meg Tirrell joins 'Closing Bell' to report that Medicare will cover Biogen's Alzheimer's drug in trials.

Biogen Inc. BIIB, +2.64% shares fell more than 6% in the extended session Tuesday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said it plans to cover the

100 "Fringe" Predictions For 2022 Submitted by QTR''s Fringe Finance Having already provided my semi-lengthy look at 22 stocks that I am watching heading into 2022 (you can view that far more serious post here ), I wanted to do something more fun, and less serious to open the new year. Heading into each new year, contained herein are 80 predictions of mine - void of all analysis and disclaiming any and all guarantees that I have any idea what I’m talking about . Absolutely none of these are to be considered life advice, investment advice or solicitations to buy or sell securities, sectors or industries mentioned. Please note that I have personal financial exposure to some elements in this list and that these are nothing more than wild-ass guesses, for fun, of what I think the coming year could bring. This list is for fun only - and is all opinion only. Photo: Diginomica It’ll be fun to look back at these predictions next year, when I make a similar list for 2023. And hey, at the very least, this list will serve as a handy reference guide as to how not worth it a paid subscription to my blog can be!

Biogen Touts Alzheimer''s Drug Price-Cut As It Begs Wall Street To Give It Another Chance Looks like Biogen''s "shot at redemption" maybe might work out - although the firm isn''t out of the woods yet, not by a long shot. Biogen shares memorably surged after the FDA approved Aduhelm, the company''s "breakthrough" Alzheimer''s drug, back in June. But practically ever since, the drug has been dogged by controversy (for example, the Europeans have more or less rejected it, and three FDA advisors quit to protest the fact that it had won approval). The head of the FDA has since called an investigation , and it remains to be seen whether the drug''s approval will ultimately be walked back. Biogen cut its price for the drug in December, as a number of medical systems have declined to offer it, causing sales to dramatically disappoint Wall Street expecpectations. But on Monday, the company got a shot at redemption when it delivered a presentation at a JP Morgan health-care conference that was one of the other major events on the day''s agenda to distract from the worsening market rout.

Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was